Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, went public with 5,000,000 shares of its common stock at a public offering price of $13.00 per share, resulting in net proceeds of approximately $60.5 million after deducting underwriting discounts and commissions, and estimated offering expenses. All of the shares of common stock in the offering were sold by Ocular Therapeutix.

In honor of the occasion, Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman of the Board of Directors, rang the Closing Bell on July 25th. Amar Sawhney is a serial entrepreneur and a leading philanthropist in the Boston area.

Morgan Stanley, Cowen and Company and RBC Capital Markets acted as joint book-running managers for the offering. Oppenheimer & Co. acted as a co-manager.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and Phase 2 clinical development for glaucoma, ocular hypertension and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, was approved by the U.S. Food and Drug Administration in January 2014 to seal corneal incisions following cataract surgery.

|